Gallium dotatate ga-68

Gallium Dotatate Ga-68 is a type of radiopharmaceutical used in Positron Emission Tomography (PET) scans. It is a compound that combines the element gallium with a substance called DOTATATE, which binds to certain types of tumors. The gallium is made radioactive (Ga-68) so it can be detected by the PET scanner.

History

Gallium Dotatate Ga-68 was approved by the Food and Drug Administration (FDA) in the United States in 2016. It was developed as a diagnostic tool for neuroendocrine tumors, which are difficult to detect using traditional imaging methods.

Usage

Gallium Dotatate Ga-68 is used in PET scans to help detect and locate neuroendocrine tumors. The DOTATATE in the compound binds to somatostatin receptors, which are found in high numbers on these types of tumors. The radioactive gallium allows these tumors to be seen on the PET scan.

Procedure

The Gallium Dotatate Ga-68 is injected into the patient's bloodstream. It travels through the body and binds to the somatostatin receptors on the neuroendocrine tumors. The patient is then scanned with a PET scanner, which can detect the radiation from the gallium and create images of the tumors.

Risks and Side Effects

As with any medical procedure, there are potential risks and side effects associated with the use of Gallium Dotatate Ga-68. These may include allergic reactions, kidney damage, and radiation exposure. However, the benefits of accurately diagnosing neuroendocrine tumors often outweigh these risks.

See Also

• Radiopharmaceutical
• Positron Emission Tomography
• Neuroendocrine tumor
• Somatostatin receptor

Gallium dotatate ga-68 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia